351 related articles for article (PubMed ID: 27432877)
21. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
23. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
Semin Oncol; 2003 Apr; 30(2):127-31. PubMed ID: 12720121
[TBL] [Abstract][Full Text] [Related]
24. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.
Dimopoulos MA; Kastritis E; Ghobrial IM
Ann Oncol; 2016 Feb; 27(2):233-40. PubMed ID: 26598544
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
[TBL] [Abstract][Full Text] [Related]
26. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
27. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.
Treon SP; Gertz MA; Dimopoulos M; Anagnostopoulos A; Blade J; Branagan AR; Garcia-Sanz R; Johnson S; Kimby E; Leblond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone MJ
Blood; 2006 May; 107(9):3442-6. PubMed ID: 16410453
[TBL] [Abstract][Full Text] [Related]
28. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
29. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
30. Advances in Treatment of Waldenström Macroglobulinemia.
Durot E; Tomowiak C
Curr Oncol Rep; 2023 Nov; 25(11):1375-1386. PubMed ID: 37855849
[TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
Dimopoulos MA; Terpos E; Kastritis E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):235-7. PubMed ID: 23562304
[TBL] [Abstract][Full Text] [Related]
32. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
33. Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C; Jurczak W; Salem JE; Dimopoulos MA
Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
[TBL] [Abstract][Full Text] [Related]
34. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.
Kapoor P; Ansell SM; Braggio E
Cancer Treat Res; 2016; 169():321-361. PubMed ID: 27696269
[TBL] [Abstract][Full Text] [Related]
35. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Kanan S; Sheehy P; Chuma S; Xu L; Cao Y; Yang G; Liu X; Patterson CJ; Warren D; Hunter ZR; Turnbull B; Ghobrial IM; Castillo JJ
Blood; 2014 Jul; 124(4):503-10. PubMed ID: 24859363
[TBL] [Abstract][Full Text] [Related]
36. Emerging drugs for Waldenström's macroglobulinemia.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
[TBL] [Abstract][Full Text] [Related]
37. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N; Dhodapkar MV
Clin Adv Hematol Oncol; 2009 Oct; 7(10):677-81, 687-90. PubMed ID: 20040909
[TBL] [Abstract][Full Text] [Related]
38. Waldenström macroglobulinemia.
Kasi PM; Ansell SM; Gertz MA
Clin Adv Hematol Oncol; 2015 Jan; 13(1):56-66. PubMed ID: 25679974
[TBL] [Abstract][Full Text] [Related]
39. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation.
Migkou M; Fotiou D; Gavriatopoulou M; Dimopoulos MA
Expert Opin Drug Saf; 2021 Sep; 20(9):987-995. PubMed ID: 34137347
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
